- Home
- ALKT vs VERA Comparison
ALKT vs VERA Comparison
Compare ALKT & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALKT
- VERA
- Stock Information
- Founded
- ALKT 2007
- VERA 2016
- Country
- ALKT United States
- VERA United States
- Employees
- ALKT N/A
- VERA N/A
- Industry
- ALKT EDP Services
- VERA Biotechnology: Pharmaceutical Preparations
- Sector
- ALKT Technology
- VERA Health Care
- Exchange
- ALKT Nasdaq
- VERA Nasdaq
- Market Cap
- ALKT 3.1B
- VERA 2.8B
- IPO Year
- ALKT 2021
- VERA 2021
- Fundamental
- Price
- ALKT $38.14
- VERA $47.52
- Analyst Decision
- ALKT Buy
- VERA Strong Buy
- Analyst Count
- ALKT 9
- VERA 9
- Target Price
- ALKT $38.00
- VERA $54.33
- AVG Volume (30 Days)
- ALKT 1.0M
- VERA 1.1M
- Earning Date
- ALKT 10-30-2024
- VERA 11-07-2024
- Dividend Yield
- ALKT N/A
- VERA N/A
- EPS Growth
- ALKT N/A
- VERA N/A
- EPS
- ALKT N/A
- VERA N/A
- Revenue
- ALKT $315,562,000.00
- VERA N/A
- Revenue This Year
- ALKT $28.58
- VERA N/A
- Revenue Next Year
- ALKT $24.11
- VERA N/A
- P/E Ratio
- ALKT N/A
- VERA N/A
- Revenue Growth
- ALKT 26.73
- VERA N/A
- 52 Week Low
- ALKT $21.19
- VERA $12.28
- 52 Week High
- ALKT $41.36
- VERA $51.61
- Technical
- Relative Strength Index (RSI)
- ALKT 54.87
- VERA 55.20
- Support Level
- ALKT $35.57
- VERA $43.41
- Resistance Level
- ALKT $38.49
- VERA $46.82
- Average True Range (ATR)
- ALKT 1.37
- VERA 2.53
- MACD
- ALKT -0.22
- VERA -0.29
- Stochastic Oscillator
- ALKT 51.53
- VERA 44.39
About ALKT Alkami Technology Inc.
Alkami Technology Inc is a cloud-based digital banking solutions provider. Alkami Platform, allows FIs to onboard and engage new users, accelerate revenues and meaningfully improve operational efficiency with the support of a proprietary, true cloud-based, multi-tenant architecture.
About VERA Vera Therapeutics Inc.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.